The purpose of this study is to compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in renal impairment patients and healthy volunteers.

Inclusion Criteria:

<Renal impairment patient>

• age: 20-65 years
• eGFR: < 30ml/min/1.73m^2
• not on dialysis
• body weight: greater than 55kg
• written informed consent

<Healthy volunteer>

• age: 20-65 years
• body weight: greater than 55kg
• written informed consent

Exclusion Criteria:

• AST, ALT > 1.5 times of upper normal range
• positive drug or alcohol screening